1-7 of 7
Petro E. Petrides
Close
Sort by
Journal Articles

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

Heinz Gisslinger, MD, Christoph Klade, Kudrat Abdulkadyrov, MD, Slawomira Kyrcz-Krzemien, MD PhD, Elena Karyagina, MD, Anait L. Melikyan, MD PhD, Krzysztof Warzocha, Barbara Grohmann-Izay, MD, Juri Hodisch, MD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, Petro E. Petrides, MD PhD, Jiri Schwarz, MD PhD, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2016) 128 (22): 476.
https://doi.org/10.1182/blood.V128.22.476.476
Published: 2016
Journal Articles

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Clinical Trials & Observations
Heinz Gisslinger, Mirjana Gotic, Jerzy Holowiecki, Miroslav Penka, Juergen Thiele, Hans-Michael Kvasnicka, Robert Kralovics, Petro E. Petrides
Journal: Blood
Blood (2013) 121 (10): 1720–1728.
https://doi.org/10.1182/blood-2012-07-443770
Published: 2013
Includes: Supplemental data
Journal Articles

Long-Term Experience with Anagrelide (Thromboreductin®) In the Treatment of Essential Thrombocythemia: Data from an International Registry

Michael Steurer, Heinz Gisslinger, Miroslav Penka, Siegfried Sormann, Jiri Schwarz, Elena Tothova, Mikulas Hrubisko, Andrzej Hellmann, Maria Podolak-Dawidziak, Petro E. Petrides
Journal: Blood
Blood (2010) 116 (21): 5064.
https://doi.org/10.1182/blood.V116.21.5064.5064
Published: 2010
Journal Articles

Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) In Primary Thrombocythemia

Gillian Stephens, Ph.D., Jan Tauscher, M.D., Fabian Siegel, M.D., David R. Phillips, PhD, Patrick Andre, Ph.D., Petro E. Petrides, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 4218.
https://doi.org/10.1182/blood.V116.21.4218.4218
Published: 2010
Journal Articles

Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients

Heinz Gisslinger, Mirjana Gotic, Jerzy Holowiecki, Miroslav Penka, Juergen Thiele, Hans Michael Kvasnicka, Robert Kralovics, Petro E. Petrides
Journal: Blood
Blood (2008) 112 (11): 661.
https://doi.org/10.1182/blood.V112.11.661.661
Published: 2008
Journal Articles

Bleeding Risk in Patients with Essential Thrombocythemia and a Platelet Count of More Than 1.5 Million/μl: A Challenge of the Dogma of Mandatory Initiation of Cytoreductive Therapy.

Petro E. Petrides, MD, PhD, Fabian Siegel
Journal: Blood
Blood (2007) 110 (11): 4660.
https://doi.org/10.1182/blood.V110.11.4660.4660
Published: 2007
Journal Articles

JAK2 Mutation Screening and Chromosome Analysis Are Necessary for a Comprehensive Diagnostic Work up in CMPD: A Study on 469 Cases.

Susanne Schnittger, PhD, Torsten Haferlach, MD, Petro E. Petrides, MD, Wolfgang Kern, MD, Claudia Schoch, MD
Journal: Blood
Blood (2005) 106 (11): 4963.
https://doi.org/10.1182/blood.V106.11.4963.4963
Published: 2005